"WARD's Practical" - WhatsApp group Test link
Home
Acute Coronary Syndrome

Optimizing Dual Antiplatelet Therapy Duration After Stent Placement in Acute Coronary Syndrome

Optimizing dual antiplatelet therapy duration after stent placement in acute coronary syndrome involves balancing thrombotic and bleeding risks.

As a cardiovascular pharmacist, you will often hear debates on the optimal duration of dual antiplatelet therapy (DAPT) after stent placement in acute coronary syndrome (ACS) patients. Typically, DAPT with aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) is recommended for 12 months, with the option to extend for patients at high thrombotic and low bleeding risk.

RxPharm-adv

Consider recent evidence suggesting that 📊 1 to 3 months of DAPT may be sufficient for select ACS patients, particularly those with a high bleeding risk due to factors such as advanced age or prior gastrointestinal or intracranial bleeding. Shorter DAPT durations can reduce bleeding without increasing cardiovascular risk, partly due to advancements in stent technology. However, this remains a controversial topic.

Recognize that limited data raise concerns about the ischemic risk associated with shorter DAPT courses in ACS patients with very high thrombotic risk, such as those with multiple stents or STEMI. Currently, there is insufficient evidence to definitively support shorter DAPT durations for patients with both high bleeding and thrombotic risk.

Collaborate with cardiology colleagues to tailor DAPT duration for ACS patients with stents.

  • Adhere to the 12-month DAPT regimen for most ACS patients, especially those with a lower bleeding risk, and reassess periodically.
  • For patients where bleeding risk outweighs thrombotic risk, consider a shorter DAPT course of 1 to 3 months, followed by monotherapy with a P2Y12 inhibitor for up to 12 months, and then single antiplatelet therapy indefinitely, usually aspirin or clopidogrel.

Note that most studies on shorter DAPT durations involve clopidogrel or ticagrelor, with fewer data available on prasugrel. Ensure early post-discharge follow-up, document the planned antithrombotic duration, verify patient access to medications, and educate patients on the importance of adhering to the DAPT regimen.

RxPharm-adv

Take-home points

Dual antiplatelet therapy (DAPT) after stent placement in ACS patients is evolving...

  1. Recognize that standard DAPT duration is 12 months with aspirin and a P2Y12 inhibitor.
  2. Consider shorter DAPT durations (1 to 3 months) for patients with high bleeding risk.
  3. Acknowledge that newer stent technology helps reduce bleeding risks without increasing cardiovascular risks.
  4. Be aware of limited data and potential ischemic risks with shorter DAPT in high thrombotic risk patients.
  5. Collaborate with cardiologists to tailor DAPT duration based on individual patient risk profiles.
  6. Ensure proper follow-up, medication access, and patient education for adherence to the DAPT regimen.

References

  1. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 Mar 15;145(11):e771. doi: 10.1161/CIR.0000000000001061]. Circulation. 2022;145(3):e4-e17. doi:10.1161/CIR.0000000000001039
    2. Show more references

Keywords: Dual antiplatelet therapy, DAPT, Acute coronary syndrome, ACS, Stent placement, Cardiovascular risk, Bleeding risk, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, Stent technology, Ischemic risk

Senior clinical pharmacist, "Pharmacy Practice Department, Tanta University Hospital, Egypt". Medical content writer.